Oscar Laskin, as the President and Founder of R2D Pharma Services LLC, leverages over two decades of extensive experience in drug development, bridging the gap between scientific innovation and clinical application. His multifaceted background as a physician-scientist uniquely positions him as a leader in Translational...
Oscar Laskin, as the President and Founder of R2D Pharma Services LLC, leverages over two decades of extensive experience in drug development, bridging the gap between scientific innovation and clinical application. His multifaceted background as a physician-scientist uniquely positions him as a leader in Translational Medicine and Clinical Pharmacology, where he has made significant contributions to the advancement of antiviral therapies. At R2D Pharma Services, Oscar is at the forefront of pioneering projects that focus on optimizing drug development processes, ensuring compliance with FDA regulations, and enhancing clinical study design across various therapeutic areas, including oncology and infectious diseases.
Oscar's expertise in Clinical Research and Good Clinical Practice (GCP) is instrumental in guiding clients through the complexities of drug development, from initial concept to New Drug Application (NDA) submission. His deep understanding of drug metabolism and pharmacokinetics (DMPK) allows him to provide invaluable insights into toxicology and safety assessments, ensuring that new therapies are not only effective but also safe for patient use. As a consultant and contractor, he collaborates with both large pharmaceutical companies and emerging biotech firms, offering tailored strategies that address specific challenges in the clinical development landscape.
Recognized as a world-class authority in his field, Oscar is committed to advancing the science of drug development and improving patient outcomes. His passion for innovation and dedication to excellence drive R2D Pharma Services to deliver cutting-edge solutions that empower clients to navigate the complexities of the life sciences industry successfully.
